VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ESMO Immuno-Oncology 2022 | Fianlimab and cemiplimab in patients with advanced melanoma

Omid Hamid, MD, The Angeles Clinic and Research Institute, Los Angeles, CA, discusses findings from a subgroup analysis of a Phase I trial (NCT03005782) of fianlimab, a human lymphocyte activation gene-3 (LAG-3) monoclonal antibody, and cemiplimab in patients with advanced melanoma. In two cohorts of 80 patients who were anti-PD-(L)1 naïve, 19 patients had liver metastases and 28 had elevated lactate dehydrogenase levels. A favorable overall response rate and disease control rate were reported. Fianlimab and cemiplimab additionally were well tolerated, with only two patients reporting a grade 5 adverse event. This interview took place at the ESMO Immuno-Oncology Congress 2022 in Geneva, Switzerland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter